In all the trials completed for Avastin in the metastatic breast cancer setting, no evidence of increased overall survival was shown. BCA advocates that the FDA not approve drugs for treatment of breast cancer unless they can be shown to 1) improve overall survival, and/or 2) improve quality of life, and/or 3) cost less than therapies already available. Unfortunately, Avastin fails on all counts. The interests of patients must come before the profits of companies manufacturing the treatments. We need to continue to demand better drugs for people with metastatic disease.